Lexaria Bioscience

Historical price data

Lexaria Bioscience is a micro-cap biotech focused on commercializing its proprietary DehydraTECH™ drug delivery platform. The company's mission is to improve the performance of existing and new oral pharmaceuticals, particularly fat-soluble molecules, by increasing their bioavailability and onset speed. Its strategy is purely licensing-based, partnering with established pharmaceutical and consumer product companies to integrate DehydraTECH into their pipelines. Key achievements include a robust global patent portfolio, positive human clinical data across multiple drug classes, and a lean operational structure that extends its capital runway.

DehydraTECH™ is a patented lipid-based drug delivery platform that enhances the bioavailability and speed of onset for orally administered fat-soluble active ingredients by promoting absorption through the intestinal tract and across the blood-brain barrier.

Lexaria competes with large chemical firms and specialized biotechs in the drug delivery space. Its advantages include a broad patent portfolio, demonstrated efficacy across multiple drug classes, and a capital-efficient licensing model. The primary challenge is commercial execution and outperforming competitors with greater resources in securing pharmaceutical partnerships.